Cipla reported Q4 revenue of ₹6,541 crore and FY26 revenue of ₹28,163 crore, with an annual EBITDA margin of 21%.
The company achieved key milestones including India business surpassing ₹12,500 crore and US approval for generic Ventolin.
Management provided FY27 EBITDA margin guidance of 18.5%-20% and targets a $1 billion US revenue run-rate by year-end.
R&D investment stood at ₹1,974 crore (7% of revenue) with 40-50 products planned for filing over next three years.